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INTRODUCTION
Malignant peripheral nerve sheath tumors (MPNSTs) are
rare and highly aggressive neoplasms, representing only 5%
of soft tissue sarcomas (1,2). Approximately half of MPNST
cases occur in association with neurofibromatosis type 1
(NF1) (3). MPNSTs may appear de novo or develop from the
malignant transformation of a benign neural neoplasm,
generally a plexiform neurofibroma (1). Solitary (unasso-
ciated with NF1) and localized (or discrete; multiple in NF1)
neurofibromas do not have malignant transformation
potential (1,3). NF1 loss of heterozygosity (LOH) has been
demonstrated in NF1-associated and sporadic MPNSTs.
Although NF1 LOH is believed to be sufficient for neu-
rofibroma development, MPNST pathogenesis has been
suggested to be a multistage process that includes other
molecular alterations (4,5). TP53 mutations have been found
in a subgroup of MPNSTs, indicating that a p53-mediated
pathway is involved in their development (5,6).
Some clinicopathological features (e.g., the presence of
NF1, high histological grade, necrosis, and rhabdomyoblastic
differentiation) have been indicated to be important factors
for lower survival in MPNST cases in some studies but not in
others (2,7–10). The clinical significance of p53 expression in
MPNSTs is also a controversial issue. We aimed to study p53
expression in MPNSTs and investigate its impact, as well as
the impacts of the clinicopathological features of MPNSTs, on
the survival rates. We also compared p53 expression in
MPNSTs with their clinicopathological features and with p53
expression in neurofibromas.
MATERIALS AND METHODS
The Ethical Committee of the National Institute of Cancer
(INCA), RJ, Brazil, approved this study.
Case Selection
MPNSTs diagnosed from 1996-2005were obtained from the
pathology files of INCA. The following inclusion criteria were
used: available medical records and preserved paraffin blocks
from the resected primary tumor with a sufficient quantity of
material (in patients submitted to radiotherapy and/or
chemotherapy prior to primary tumor resection, the biopsy
material was used if it had the same histological grade as the
resected material). Tumors with one of the following features
were included: arose within a peripheral nerve; arose during
the transition from a benign neural tumor; developed in aNF1
patient and exhibited the same histological features of most
MPNSTs originating from a nerve; and developed in a non-
NF1 patient, exhibited the same histological features as most
MPNSTs and expressed S-100 (Dako Corp., Carpinteria, CA,
USA, 1:4,000) and/or CD57 (clone TB01; Dako, 1:50). All
samples were immunoreactive for anti-vimentin (clone V9;
Dako, 1:800) and negative for anti-cytokeratin (clone AE1/
AE3; Dako, 1:400), anti-melanosome, (clone HMB-45, 1:200),
anti-actin (smoothmuscle; clone 1A4; Dako, 1:250), anti-actin/
muscle (clone HHF35; Dako, 1:1,000), and anti-desmin (clone
D33; Dako, 1:100) antibodies, except the malignant triton
tumors, which exhibited anti-actin/muscle and desmin
immunopositive areas. The immunohistochemistry (IHC)
was performed after reviewing the H&E sections.
Plexiform neurofibromas diagnosed from 1996-2005 were
obtained from the pathology files of INCA. The following
inclusion criteria were used: available medical records,
preserved paraffin blocks with sufficient quantity of
material and presence of heterogeneous and diffuse
expression of S-100 protein. The other selected neurofibro-
mas had been used in two previous studies (11,12).
The diagnoses of all the MPNSTs and neurofibromas were
confirmed by two pathologists.
Histological Analysis of Malignant Peripheral Nerve
Sheath Tumors
Tables 1 and 2 show the clinical and pathological features,
respectively, of the MPNSTs analyzed in this research. The
tumors were classified as low- or high-grade according to
the Armed Forces Institutes of Pathology criteria (1).
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The epithelioid MPNSTs included in this study were com-
posed predominantly of epithelioid cells and exhibited spindle
cells identical to those of conventional MPNSTs. The malig-
nant triton tumors had areas of cells with rhabdomyoblast
morphology, which expressed desmin and/or actin/muscle.
Construction of Tissue Microarray Paraffin Blocks
Two tissue microarray (TMA) paraffin blocks containing
samples from all tumors were constructed. Five morpholo-
gically representative regions of each tumor were marked
with a colored pen on the glass slides of H&E sections.
Areas of necrosis and severe inflammatory infiltration were
avoided. From each corresponding original paraffin block,
five tissue cores (1.1 mm in diameter) were sampled from
the marked areas in the donor block and mounted onto a
recipient paraffin block, using the alternative method for the
manual construction of TMAs (13).
Immunohistochemistry
Sections of 3 mm in thickness were cut and collected on
silane-coated slides. After dewaxing, the p53 protein
expression was assessed by IHC (anti-p53 antibody; clone
DO-7; Dako Corporation, 1:100) using a protocol described
elsewhere (14). A metastatic carcinoma was used as the
positive control, and the omission of the primary antibody
was used to establish the negative control.
The quantification of the p53 staining was performed
with computerized digital image analysis (Image-Pro Plus
software v4.5; Media Cybernetics), as previously described
(14). The quantification was expressed as the positivity
index (PI), which was defined as the p53-positive area
divided by the tissue area. The tumors were classified
as having low or high PIs (cut-off value = 0.0020). The
intensity of the p53 expression (weak, moderate, or intense)
was also evaluated.
Statistical Analysis
Clinicopathological and immunohistochemical variables
were compared using the chi-squared, Fisher’s exact,
Student’s t-, and Mann-Whitney U tests. The Kaplan-
Meier method was used to evaluate the survival curves.
The statistical significance of the clinicopathological
variables was determined with the log-rank test.
Multivariate analysis was performed using the Cox
regression model. SPSS software v.11 was used for the
statistical analyses. Differences were considered signifi-
cant if p,0.05.
RESULTS
Twenty-eight MPNSTs and thirty-eight neurofibromas
were included in this study.
Figures 1A–1C show some examples of MPNST included
in the study (malignant triton tumor and MPNST with
chondrosarcoma differentiation).
The overall and disease-free five-year survival rates of
the MPNST patients were 46 and 39%, respectively. The
data regarding the p53 expression in the MPNSTs and
neurofibromas are described in Tables 2 and 3. p53
expression was more common in the MPNSTs than in the
Table 2 - Pathological data of the malignant peripheral nerve sheath tumors.
Case
number
Size
(cm) Grade Presence of heterologous differentiation Necrosis
Mitotic index
(mitotic figures in
10 high-power fields)* p53 PI values
1 4.6 high no no 7.0 (s.d. = 2.0) 0.00070
2 17.0 high rhabdomyosarcomatous areas yes 9.3 (s.d. = 1.5) 0.00
3 15.0 high no yes 5.3 (s.d. = 1.2) 0.00020
4 21.0 high rhabdomyosarcomatous areas yes 17.0 (s.d. = 2.0) 0.01597
5 7.0 low chondrosarcomatous areas no 3.7 (s.d. = 1.5) 0.00010
6 21.0 high no yes 7.0 (s.d. = 3.5) 0.00
7 10.0 high no no 9.0 (s.d. = 2.0) 0.00
8 16.0 low no no 0.3 (s.d. = 0.6) 0.00090
9 — high no no 18.0 (s.d. = 4.0) 0.00160
10 28.0 high no yes 19.0 (s.d. = 1.0) 0.00050
11 17.0 high no yes 13.0 (s.d. = 2.6) 0.00280
12 — high no yes 10.7 (s.d. = 1.5) 0.00040
13 13.0 high chondrosarcomatous areas yes 10.3 (s.d. = 5.7) 0.00
14 — high no no 10.3 (s.d. = 4.0) 0.00
15 — low epithelioid no 3.0 (s.d. = 0.0) 0.00
16 — high no yes 7.0 (s.d. = 2.6) 0.00170
17 13.0 high epithelioid yes 7.3 (s.d. = 1.2) 0.00
18 12.0 high chondrosarcomatous area no 6.0 (s.d. = 2.0) 0.00
19 6.0 low no no 2.3 (s.d. = 1.5) 0.00200
20 — low no no 3.0 (s.d. = 1.0) 0.00030
21 — high no yes 7.0 (s.d. = 2.0) 0.00
22 23.0 high no yes 13.3 (s.d. = 3.2) 0.00060
23 5.0 high chondroma area no 7.0 (s.d. = 2.0) 0.00010
24 10.0 low no no 3.7 (s.d. = 1.5) 0.01610
25 13.0 low no no 3.7 (s.d. = 1.2) 0.00320
26 3.0 high no no 6.7 (s.d. = 0.6) 0.00050
27 11.0 high no no 13.0 (s.d. = 3.0) 0.00640
28 — high no yes 8.0 (s.d. = 1.0) 0.00
— information not available (the tumor resection was performed at another institution); PI, positivity values *, in each case, at least 30 fields were
analyzed, and the mean value of the sum of the mitotic figures in 10 high-power fields is shown in the table.
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neurofibromas (x2 p,0.001). The only p53-positive neurofi-
broma (plexiform neurofibroma) presented weak nuclear
immunoreactivity. In the MPNSTs, the nuclear p53 expres-
sion varied from weak to intense.
Figures 1D–1F show the expression of p53 in the plexi-
form neurofibroma and in two MPNSTs.
The p53 expression was not correlated with any of the
following clinicopathological features of MPNSTs (Fisher’s
exact test): NF1 (p= 0.433), local recurrence (p = 0.642),
metastasis (p= 0.125), high grade (p = 0.364), high mitotic
index (p= 0.278), and necrosis (p = 0.249).
In the p53-positive MPNSTs, there was no correlation of
high PI with the clinicopathological variables (Mann-
Whitney test): NF1 (p= 0.179), local recurrence (p = 0.643),
metastasis (p = 0.353), high grade (p = 0.208), high mitotic
index (p = 0.156), and necrosis (p = 0.387).
The epithelioid variant (p = 0.036) was the only significant
variable in the log-rank analysis of disease-free survival
(Table 4). The Cox regression analysis showed that necrosis
(p= 0.024) was an independent prognostic factor for lower
overall survival (p= 0.007) (Table 5).
DISCUSSION
The five-year overall survival rate of patients with
MPNSTs has been reported to range from 23% to approxi-
mately 50% (2,15–17), similar to the rate of 46% found in this
study. In our study, seven patients censored in the overall
survival calculation had recurrence or metastasis, and three
patients were lost to follow-up when the disease became
terminal. Their deaths most likely went unobserved; there-
fore, their overall survival time may have been overesti-
mated. This issue is usually a bias inherent in retrospective
studies that intend to measure overall survival.
Although some authors have demonstrated the correla-
tion of various clinicopathological parameters with the
biological behavior of the MPNSTs, there is no consensus
with regard to the importance of these factors in the
prognosis of MPNST (2,7–10). In our study, the presence
of necrosis was an independent predictor of mortality.
In the present work, only one (2.6%) neurofibroma
(plexiform neurofibroma) expressed p53. Other studies
have also demonstrated that p53 expression is rare or
absent in neurofibromas (18–21). In contrast, the majority
(64.3%) of MPNSTs expressed p53. Our results are similar to
those of previous studies that used the same anti-p53
antibody clone, and the results of these studies showed that
p53 expression in the MPNSTs varies from 42 to 100%
(6,9,16,18–20,22). To our knowledge, there are only two
previous studies that used TMA technology to investigate
p53 expression in MPNSTs (16,22).
In some studies (9,20,21), an association between p53
expression and histological grade was observed, which
differs from our research and that of others (18,19). One
explanation for these divergent results could be the different
criteria adopted for histological gradation. Although the
United States National Institutes of Cancer and Fe´de´ration
Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
grading systems are the most commonly used systems for
sarcomas, the histological grading systems for sarcomas
have no prognostic value for some histological subtypes,
including MPNSTs (23). Therefore, we preferred to use a
Figure 1 - Malignant triton tumor: case 4 (A and B). A. Area of
differentiation in the rhabdomyosarcoma (arrows); H&E, 40x. B.
Cells immunopositive for desmin; immunohistochemistry (diami-
nobenzidine), 40x. C. Malignant peripheral nerve sheath tumor
with heterologous differentiation in a chondrosarcoma: case 13;
H&E, 20x. D. p53-immunopositive plexiform neurofibroma
(arrow); immunohistochemistry (diaminobenzidine), 40x. E.
Malignant peripheral nerve sheath tumor immunoreactive for
p53: case 24; immunohistochemistry (diaminobenzidine), 40x. F.
Malignant peripheral nerve sheath tumor immunoreactive for
p53: case 4; immunohistochemistry (diaminobenzidine), 40x.
OBS: positive cells in brown.
Table 3 - Immunohistochemical data of neurofibromas and malignant peripheral nerve sheath tumors.
Group % of positive cases (n) Mean PI
Standard
deviation Median PI PI min/max IQ range
Neurofibromas 2.6% (n=1) 0.0005 — — 0.0000/0.0005 —
Plexiform neurofibromas 6.3% (n=1) 0.0005 — — 0.0000/0.0005 —
Neurofibromas (from NF1 and
non-NF1 patients)
0.0% (n=0) — — — — —
MPNSTs 64.3% (n=18) 0.001931 0.0042199 0.000350 0.0000/0.01597 0.0017
PI, positivity index; IQ, interquartile; MPNSTs, malignant peripheral nerve sheath tumors.
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simple system in which MPNSTs are classified into two
grades: low and high (1).
We could not observe any influence of p53 expression on
survival rates, similar to the results of a previous study (24).
In contrast, other researchers showed that p53 expression
was an important predictive factor for lower survival rate
(16,19). In some studies (16,22), p53 expression was more
common in neurofibromas associated with NF1 than in
those not associated with NF1, but other studies (20) did not
observe this association, similar to our results. There are a
few possible explanations for these divergent results. First,
some authors considered all cases that had any immuno-
positive cells as being positive, whereas others established
cut-off points, varying from 3 to 10% of positive cells (9,20–
22,24). Another important factor is that all previous studies
used conventional pathologist-based manual scoring to
quantify the p53 staining, which increases the inter-observer
and intra-observer variabilities. Our study was the first to
use computerized image analysis to calculate the p53
expression. Moreover, technical considerations, such as the
storage time of the tissue sections on glass slides, can
influence p53 immunoreactivity.
Table 4 - Results of the influence of the clinicopathological variables on the overall and disease-free survival in patients
with malignant peripheral nerve sheath tumors.
Variables
Total SV
(months)
Total SV
(p log-rank) Disease-free SV (months) Disease-free SV (p log-rank)
Gender
Female
Male
54.3
23.5
0.109 47.3
19.3
0.118
NF1
Yes
No
31.6
59.9
0.044 31.4
41.6
0.959
Location
Trunk (yes/no)
Limbs (yes/no)
Lower limb (yes/no)
Upper limb (yes/no)
Head and neck (yes/no)
49.4/42.2
37.9/47.0
37.7/46.4
12.2/46.1
49.0/48.9
0.955
0.937
0.980
0.912
0.977
47.3/27.4
25.0/50.5
21.9/50.8
11.4/40.1
50.2/39.7
0.390
0.199
0.108
0.679
0.531
Treatment performed
Surgical resection + radiotherapy
Other type of treatment
35.9
60.0
0.184 35.886
55.629
0.282
Size of the tumor
#5 cm
.5 cm
44.7
57.6
0.716 28.9
55.4
0.610
Free surgical margins
Yes
No
49.7
55.1
0.925 48.57
41.5
0.516
Local Recurrence
Yes
No
46.0
60.6
0.606 — —
Metastases
Yes
No
54.4
23.4
0.135 — —
Histological Grade
High
Low
31.7
68.6
0.045 23.94
65.28
0.095
Mitotic index
$ 10 mitoses/10 high-power fields
, 10 mitoses/10 high-power fields
24.0
53.7
0.051 21.54
44.77
0.386
Necrosis
Yes
No
19.1
62.4
0.003 23.95
50.23
0.138
Epithelioid Variant
Yes
No
*
44.49
* 6.21
43.98
0.036
Malignant Triton Tumor
Yes
No
9.2
46.3
0.566 18.42
42.26
0.958
Chondrosarcoma differentiation
Yes
No
54.5
43.8
0.511 46.17
37.89
0.356
P53 protein expression
Positive
Negative
Low PI
High PI
43.8
50.9
38.9
43.5
0.942
429
49,1
42.6
46.9
49.4
0.418
0.502
SV, survival; PI, positive index; *, the value could not be calculated because all cases were censored.
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Necrosis was an important prognostic factor for lower
overall survival, and the epithelioid variant was an
important prognostic factor for shorter disease-free survival.
p53 expression was not associated with any clinicopatholo-
gical features and did not have an impact on the survival
rates of the MPNST patients. p53 expression was rare in the
neurofibromas and common in the MPNSTs, showing that
the p53 pathway most likely plays an important role in the
tumorigenesis of MPNSTs.
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Table 5 - Results of the Cox regression model for
significant variables in the univariate analysis of overall
survival.
Steps Co-variables p-value Exp (B) 95% CI for Exp (B)
lower upper
1 Presence of NF1
Histological
Grade
Necrosis
Mitotic Index
0.497
0.846
0.276
0.370
0.627
1.233
0.426
1.076
0.163
0.161
0.092
0.917
2.413
9.283
1.975
1.262
2 Presence of NF1
Necrosis
Mitotic Index
0.465
0.255
0.289
0.609
0.413
1.083
0.161
0.090
0.935
2.301
1.897
1.254
3 Necrosis
Mitotic Index
0.143
0.226
0.343
1.093
0.082
0.947
1.434
1.261
4 Necrosis 0.007 0.199 0.062 0.639
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